Imagine what people in communities across Pennsylvania are thinking as Penn State fuels speculation that some of its branch campuses might be targeted for possible closing — in large part by remaining tight-lipped about which campuses could be in danger of being shuttered. We suspect ...
We believe the fifth circuit of the U.S. Court of Appeals made the correct decision last week when it struck down a federal law prohibiting 18-, 19- and 20-year-olds from purchasing handguns. “Ultimately, the text of the Second Amendment includes eighteen-to-twenty-year-old individuals ...
Head Start has been something of a sacred cow in Washington since its creation in 1965. The $12.3 billion federal program provides pre-school services to nearly 790,000 low-income children each year. But a report released last week by the Government Accountability Office reveals serious negligence and fiscal mismanagement in Head Start, putting at risk the very children the program claims to help. The report studies Head Start programs that are operating under interim management, meaning those whose former managers—usually local agencies or nonprofits—gave up or lost their federal ...
We congratulate Scott Bessent on his confirmation as the United States’ next secretary of the treasury, and believe he has outlined a philosophy that can help America get back on track. Some specific issues on which we are buoyed by his confirmation include the minimum wage, the national ...
We are hopeful about a plan to construct new housing in Hughesville and Wolf Township. Shannon Rossman, director of planning and community development for Lycoming County, offered the Sun-Gazette a thorough explanation for an article in Wednesday’s edition for the proposal and the steps it ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic version cost $99 for the same amount, according to the Biosimilars Council. Now, in a rational world, insurers would immediately switch to the generic drug so patients with diabetes could save money. Instead, pharmacy benefit managers — which determine what drugs insurers cover under what terms — wouldn’t put the unbranded drug into ...
